Reduced frequency & intensity of migraine attacks after single dose of psilocybin

Psilocybin – the active ingredient in psychedelic mushrooms – shows promise for the transitional treatment of episodic migraines in early clinical trials, according to a review from Yale School of Medicine’s Emmanuelle Schindler, M.D., Ph.D.  In the first and only…

Predicting who may do best with psychedelic-assisted therapy

A new research review identifies personality traits that have been associated with positive and negative experiences on psychedelics being tested for therapeutic purposes in previous studies, information that could help predict how future clinical trial participants will respond to the drugs.